Breast cancer metastatic phenotype as predicted by histologic tumor markers

Cancer Journal from Scientific American

Volumn 3, Issue 4, 1997, Pages 224-229

  Heimann, Ruth ^a   Ferguson, Donald ^a   Recant, Wendy M ^b   Hellman, Samuel ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Breast cancer virulence; Histologic markers; PCNA; Tumor nuclear grade

Indexed keywords

CYCLINE; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GRADING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL NUCLEUS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PARAFFIN EMBEDDING; PHENOTYPE; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0030851435     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hellman S. Karnofsky Memorial Lecture: natural history of small breast cancers. J Clin Oncol 1994;12:2229-2234.
2. Celis JE, Celid A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A 1985;82:3262-3266.
3. Bravo R, Fey SJ, Bellatin J et al. Identification of a nuclear and of a cytoplasmic polypeptide whose relative proportions are sensitive to changes in the rate of cell proliferation. Exp Cell Res 1981;136: 311-319.
4. Bianchi S, Paglierani M, Zampi G et al. Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer 1993;72:120-125.
5. Garcia RL, Coltera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Am J Pathol 1989;134:733-739.
6. Ferguson DJ, Meier P, Karisson T et al. Staging of breast cancer and survival rates: an assessment based on 50 years of experience with radical mastectomy. JAMA 1982;248:1337-1341.
7. Heimann R, Ferguson D, Powers C et al. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996;88:1764-1769.
8. Quiet CA, Ferguson DJ, Weichselbaum RR et al. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow up. J Clin Oncol 1995;13:1144-1151.
9. Quiet CA, Ferguson DJ, Weichselbaum RR et al. Natural history of node-positive breast cancer: the curability of small cancers with limited number of positive nodes. J Clin Oncol 1996:3105-3111.
10. Miller RT. Immunohistochemistry in the community practice of pathology. Laboratory Medicine 1991;22:527-532.
11. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980;15:239-251.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53:457-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 1966;50:163-170.
14. Bravo R, Frank R, Blundell PA et al. Cyclin-PCNA is the auxiliary protein of DNA polymerase delta. Nature 1987;326:515-517.
15. Mathews MB, Bernstein RM, Franza BR Jr. et al. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984;309: 374-376.
16. Battersby S, Anderson TJ. Correlation of proliferative activity in breast tissue using PCNA/cyclin. Hum Pathol 1990;21:781.
17. Tahan SR, Neurberg DS, Dieffenbach A et al. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 1993;71:3552-3559.
18. Schonborn I, Zschiesche W, Minguillon C et al. Prognostic value of proliferating cell nuclear antigen and c-erb-2 compared with conventional histopathological factors in breast cancer. Journal of Cancer Research and Clinical Oncology 1995;121:115-122.
19. Russo A, Bazan V, Morello V et al. Vimentin expression, proliferating cell nuclear antigen and flow cytometric factors: prognostic role in breast cancer. Anal Quant Cytol Histol 1994;16:365-374.
20. Haerslev T, Jacobsen GK. Proliferating cell nuclear antigen in breast carcinoma: an immunohistochemical study with correlation to histopathological features and prognostic factors. Virchows Arch 1994;424:39-46.
21. Tubiana M, Pejovic MH, Koscielny S et al. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 1989;47:17-22.
22. Gelman R, Nixon AJ, O'Neill A et al. Change over time in the effect of grade and ER on risk of distant failure in patients treated with breast conserving therapy [abstract]. Int J Radiat Oncol Biol Phys 1996;36[1S]:181.
23. Hilsenbeck SG, Ravdin PM, de Moor CA et al. Paradoxical decreases in prognostic utility as datasets mature: time-dependent lack of prognostic factors in primary breast cancer. Breast Cancer Res Treat 1996;37[S]:35.
24. Kinne DW, Ashikan R, Butler A et al. Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 1981;47: 2364-2367.
25. Butler JA, Bretsky S, Mendez-Botet C et al. Estrogen receptor protein of breast cancer as a predictor of recurrence. Cancer 1985;55: 1178-1181.
26. Pichon MF, Broet P, Magdelenat H et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996;73:1545-1551.